243 related articles for article (PubMed ID: 33062717)
1. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
Shang A; Wang W; Gu C; Chen C; Zeng B; Yang Y; Ji P; Sun J; Wu J; Lu W; Sun Z; Li D
J Exp Clin Cancer Res; 2019 Sep; 38(1):411. PubMed ID: 31533774
[TBL] [Abstract][Full Text] [Related]
4. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
Yasuoka H; Asai A; Ohama H; Tsuchimoto Y; Fukunishi S; Higuchi K
Sci Rep; 2020 Jun; 10(1):10377. PubMed ID: 32587357
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.
Pawłowska A; Suszczyk D; Tarkowski R; Paduch R; Kotarski J; Wertel I
Cancer Manag Res; 2020; 12():9691-9709. PubMed ID: 33116828
[TBL] [Abstract][Full Text] [Related]
6. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
[No Abstract] [Full Text] [Related]
7. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
10. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
Maine CJ; Aziz NH; Chatterjee J; Hayford C; Brewig N; Whilding L; George AJ; Ghaem-Maghami S
Cancer Immunol Immunother; 2014 Mar; 63(3):215-24. PubMed ID: 24297569
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
16. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
Suszczyk D; Skiba W; Zardzewiały W; Pawłowska A; Włodarczyk K; Polak G; Tarkowski R; Wertel I
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232911
[TBL] [Abstract][Full Text] [Related]
17. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
[TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
